Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
(NASDAQ: KOD) Delayed: 32.71 -0.14 (0.43%)
Previous Close $32.85    52 Week High $ 
Open $32.78    52 Week Low $ 
Day High $32.82    P/E N/A 
Day Low $31.54    EPS $ 
Volume 1,608,964